CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH This Research Article from Blood – available as a PDF – discusses two main points. First, antibody response to BNT162b2 mRNA COVID19 vaccine in CLL patients is markedly impaired and affected by disease activity and treatment. The second point shows that, in patients treated with either Bruton’s tyrosine kinase inhibitors (TKIs) or venetoclax ± anti-CD20 antibody, responses are relatively low.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
